Summary

Asia Pacific Plasma Protease C1-Inhibitor Market is valued approximately at USD 787.98 million in 2023 and is anticipated to grow with a healthy growth rate of more than 19.48% over the forecast period 2024-2032. Plasma Protease C1-Inhibitor, also known as C1-INH or C1 esterase inhibitor, is a protein found in the blood that plays a crucial role in regulating the complement system and controlling inflammation. It is a natural inhibitor of several proteases, including C1s and C1r, which are part of the classical pathway of the complement system. By inhibiting these proteases, C1-INH helps to prevent excessive activation of the complement cascade and the generation of inflammatory mediators, thereby maintaining immune homeostasis and preventing tissue damage. The increasing adoption of biotechnology and precision medicine is a key trend supporting the growth of Asia Pacific Plasma Protease C1-Inhibitor Market during the forecast period 2024-2032. Targeted treatments for hereditary angioedema (HAE) and similar disorders are becoming increasingly popular as a result of developments in genetic testing, molecular diagnostics, and tailored therapy. This involves the use of medicines utilizing plasma protease C1 inhibitors that are customized to the unique profiles of each patient, leading to better treatment success and fewer adverse effects.

Asia Pacific region is witnessing significant growth in the Plasma Protease C1-Inhibitor Market, driven by several key factors including the increasing prevalence of Hereditary Angioedema (HAE) across Asia Pacific countries, creating a greater demand for effective treatment such as Plasma Protease C1-Inhibitors. Moreover, improvements in healthcare infrastructure and accessibility to specialized therapies are expanding the market's reach to a larger patient population. Enhanced awareness and higher diagnosis rates of HAE among healthcare professionals are also contributing to the market growth, resulting to a surge in demand for Plasma Protease C1-Inhibitor products. Furthermore, favorable regulatory policies and approvals, coupled with growing healthcare expenditure and investment in rare disease treatments, are creating a supportive environment for Plasma Protease C1-Inhibitor therapies in the Asia Pacific region. These driving factors collectively leverage various growth prospects for the Plasma Protease C1-Inhibitor Market. However, high price of esoteric testing procedures and stringent regulatory requirements is expected stifle market growth between 2022 and 2032.

The key countries considered for the Asia Pacific Plasma Protease C1-Inhibitor Market study includes China, India, Japan, South Korea, Australia and Rest of Asia Pacific. In 2023, China was the largest regional market in terms of revenue because the Chinese government provides treatment and awareness of rare illnesses as their highest priority. The market for C1 inhibitors is likely to be significantly impacted by policies that accelerate orphan drug applications as well as lower costs by increasing patient access to these drugs. Moreover, the growing awareness of Hereditary Angioedema (HAE), coupled with the rising focus on improving domestic healthcare are the further factors that are bolstering the regional market growth at a substantial rate. Whereas, the market in India is expected to rise at the fastest rate over the forecast period.

Major market player included in this report are:
CSL Limited (CSL Behring LLC)
Takeda Pharmaceutical Company Limited (Shire Pharmaceutical Holdings)
Pharming Group
Company 4
Company 5
Company 6
Company 7
Company 8
Company 9
Company 10

The detailed segments and sub-segment of the market are explained below:

By Drug Type
C1-inhibitors
Kallikrein Inhibitor
Selective Bradykinin B2 Receptor Antagonist

By Dosage Form
Lyphophlised
Injectables

By Region:
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032

Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and country level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market

ページTOPに戻る

Table of Contents

Chapter 1. Asia Pacific Plasma Protease C1-Inhibitor Market Definition and Research Assumptions
1.1. Research Objective
1.2. Market Definition
1.3. Research Assumptions
1.3.1. Inclusion & Exclusion
1.3.2. Limitations
1.3.3. Supply Side Analysis
1.3.3.1. Availability
1.3.3.2. Infrastructure
1.3.3.3. Regulatory Environment
1.3.3.4. Market Competition
1.3.3.5. Economic Viability (Consumer’s Perspective)
1.3.4. Demand Side Analysis
1.3.4.1. Regulatory frameworks
1.3.4.2. Technological Advancements
1.3.4.3. Environmental Considerations
1.3.4.4. Consumer Awareness & Acceptance
1.4. Estimation Methodology
1.5. Years Considered for the Study
1.6. Currency Conversion Rates

Chapter 2. Executive Summary
2.1. Asia Pacific Plasma Protease C1-Inhibitor Market Size & Forecast (2022- 2032)
2.2. Regional Summary
2.3. Segmental Summary
2.3.1. By Drug Type
2.3.2. By Dosage Form
2.4. Key Trends
2.5. Recession Impact
2.6. Analyst Recommendation & Conclusion
Chapter 3. Asia Pacific Plasma Protease C1-Inhibitor Market Dynamics
3.1. Market Drivers
3.2. Market Challenges
3.3. Market Opportunities
Chapter 4. Asia Pacific Plasma Protease C1-Inhibitor Market: Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economic
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Asia Pacific Plasma Protease C1-Inhibitor Market Size & Forecasts by Drug Type 2022-2032
5.1. C1-inhibitors
5.2. Kallikrein Inhibitor
5.3. Selective Bradykinin B2 Receptor Antagonist
Chapter 6. Asia Pacific Plasma Protease C1-Inhibitor Market Size & Forecasts by Dosage Form 2022-2032
6.1. Lyphophlised
6.2. Injectables
Chapter 7. Asia Pacific Plasma Protease C1-Inhibitor Market Size & Forecasts by Country 2022-2032
7.1. China Plasma Protease C1-Inhibitor Market
7.1.1. Drug Type breakdown size & forecasts, 2022-2032
7.1.2. Dosage Form breakdown size & forecasts, 2022-2032
7.2. India Plasma Protease C1-Inhibitor Market
7.3. Japan Plasma Protease C1-Inhibitor Market
7.4. Australia Plasma Protease C1-Inhibitor Market
7.5. South Korea Plasma Protease C1-Inhibitor Market
7.6. Rest of Asia Pacific Plasma Protease C1-Inhibitor Market
Chapter 8. Competitive Intelligence
8.1. Key Company SWOT Analysis
8.1.1. Company 1
8.1.2. Company 2
8.1.3. Company 3
8.2. Top Market Strategies
8.3. Company Profiles
8.3.1. CSL Limited (CSL Behring LLC)
8.3.1.1. Key Information
8.3.1.2. Overview
8.3.1.3. Financial (Subject to Data Availability)
8.3.1.4. Product Summary
8.3.1.5. Market Strategies
8.3.2. Takeda Pharmaceutical Company Limited (Shire Pharmaceutical Holdings)
8.3.3. Pharming Group
8.3.4. Company 4
8.3.5. Company 5
8.3.6. Company 6
8.3.7. Company 7
8.3.8. Company 8
8.3.9. Company 9
8.3.10. Company 10
Chapter 9. Research Process
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes